US2022193230A1PendingUtilityA1
Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same
Est. expiryDec 12, 2031(~5.4 yrs left)· nominal 20-yr term from priority
A61K 39/00114A61K 2039/55538A61K 2039/55533A61K 39/39C07K 14/54C12N 2730/10171A61K 41/00C07K 14/5443A61K 38/2086C12N 7/00A61K 39/292A61K 2039/525A61P 31/18C07K 14/5434A61P 31/12A61P 37/04A61K 2039/53A61K 38/20A61P 31/22A61K 38/208A61P 31/20A61P 33/06A61P 31/16A61P 43/00A61K 39/245C12N 2730/10134C12N 2710/16034A61K 39/0005C12N 2510/00
75
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Nucleic acid molecules and compositions comprising: a nucleic acid sequence that encodes IL-12 p35 subunit or a functional fragment thereof and/or a nucleic acid sequence that encodes IL12 p40 subunit or a functional fragment thereof, are disclosed. The nucleic acid molecules and compositions further comprising a nucleic acid sequence that encodes an immunogen are also disclosed. Method of modulating immune response and methods of inducing an immune response against an immunogen are disclosed. Therapeutic and prophylactic vaccination methods are also disclosed.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 .- 67 . (canceled)
68 . A composition that comprises a) a nucleic acid sequence that encodes a functional fragment of IL-12 p35 subunit and b) a nucleic acid sequence that encodes a functional fragment of IL-12 p40 subunit, wherein
the nucleic acid sequence that encodes a functional fragment of IL-12 p35 subunit is at least 80% homologous to SEQ ID NO:1 and encodes a protein at least 80% homologous to SEQ ID NO:2, and the nucleic acid sequence that encodes a functional fragment of IL-12 p40 subunit is at least 80% homologous to SEQ ID NO:3 and encodes a protein at least 80% homologous to SEQ ID NO:4.
69 . The composition of claim 68 comprising
the nucleic acid sequence that encodes a functional fragment of IL-12 p35 subunit is at least 83% homologous to SEQ ID NO:1 and encodes a protein at least 83% homologous to SEQ ID NO:2, and
the nucleic acid sequence that encodes a functional fragment of IL-12 p40 subunit is at least 83% homologous to SEQ ID NO:3 and encodes a protein at least 83% homologous to SEQ ID NO:4.
70 . The composition of claim 68 comprising
the nucleic acid sequence that encodes a functional fragment of IL-12 p35 subunit is at least 85% homologous to SEQ ID NO:1 and encodes a protein at least 85% homologous to SEQ ID NO:2, and
the nucleic acid sequence that encodes a functional fragment of IL-12 p40 subunit is at least 85% homologous to SEQ ID NO:3 and encodes a protein at least 85% homologous to SEQ ID NO:4.
71 . The composition of claim 68 comprising
the nucleic acid sequence that encodes a functional fragment of IL-12 p35 subunit is at least 87% homologous to SEQ ID NO:1 and encodes a protein at least 87% homologous to SEQ ID NO:2, and
the nucleic acid sequence that encodes a functional fragment of IL-12 p40 subunit is at least 87% homologous to SEQ ID NO:3 and encodes a protein at least 87% homologous to SEQ ID NO:4.
72 . The composition of claim 68 formulated for delivery to an individual using electroporation.
73 . The composition of claim 68 , wherein the nucleic acid sequence that encodes IL-12 p35 subunit is on a different nucleic acid molecule than the nucleic acid sequence that encodes IL-12 p40 subunit.
74 . The composition of claim 68 , wherein the nucleic acid sequence that encodes IL-12 p35 subunit is on a plasmid and the nucleic acid sequence that encodes IL-12 p40 subunit is on a different plasmid.
75 . The composition of claim 68 , wherein the nucleic acid sequence that encodes IL-12 p35 subunit and the nucleic acid sequence that encodes IL-12 p40 subunit are on the same nucleic acid molecule.
76 . The composition of claim 68 , wherein the nucleic acid sequence that encodes IL-12 p35 subunit and the nucleic acid sequence that encodes IL-12 p40 subunit are on the same plasmid.
77 . The composition of claim 68 , wherein the nucleic acid sequence that encodes IL-12 p35 subunit and the nucleic acid sequence that encodes IL-12 p40 subunit are on the same nucleic acid molecule and operably linked to different promoters.
78 . The composition of claim 68 , wherein the nucleic acid sequence that encodes IL-12 p35 subunit and the nucleic acid sequence that encodes IL-12 p40 subunit are on the same plasmid and operably linked to different promoters.
79 . The composition of claim 68 further comprising a nucleic acid sequence that encodes an immunogen.
80 . The composition of claim 68 further comprising a nucleic acid sequence that encodes an immunogen from a pathogen selected from the group consisting of:
HIV, HPV, HCV, Influenza, Smallpox, Chikungunya, foot and mouth disease virus, Malaria, human cytomegalovirus, human respiratory syncytial virus, and MRSA.
81 . The composition of claim 68 , wherein the nucleic acid sequence that encodes IL-12 p35 subunit and the nucleic acid sequence that encodes IL-12 p40 subunit are incorporated into a viral particle.
82 . The composition of claim 68 further comprising a nucleic acid sequence that encodes one or more proteins selected from the group consisting of: IL-15 and IL-28.
83 . A method of inducing an immune response against an immunogen comprising administering to an individual, a composition of claim 68 in combination with a nucleic acid sequence that encodes an immunogen in an amount effective to induce an immune response in said individual.
84 . The method of claim 83 , wherein the composition further comprises a nucleic acid sequence that encodes an immunogen.Join the waitlist — get patent alerts
Track US2022193230A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.